DRKS00027106已完成不适用
Prospective, longitudinal cohort study of follow-up in patients with COVID-19 infection and requiring inpatient treatment for respiratory disease - COVAS
niversitätsklinikum der RWTH Aachen0 个研究点目标入组 278 人开始时间: 2021年11月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 278
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Age of majority
- •Written declaration of consent
- •Persons who are legally competent and mentally able to able to follow the instructions of the study staff.
排除标准
- •Younger than 18 years (20 years for Japanese nationality)
- •Pregnant and breastfeeding women (will be asked)
- •Immobility with need for care
- •Lack of maturity
研究者
相似试验
进行中（未招募）
1 期
A study aiming to collect data and provide a better understanding of the long-term outcome of imlifidase in treatment of immunological graft rejection in kidney transplant patientsAntibody-mediated rejection in kidney transplant patientsMedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004777-49-ATHansa Biopharma30
已完成
不适用
Prospective cohort study evaluating the long-term outcome after endoscopic submucosal dissection for colorectal neoplasia.Colorectal neoplasia can be treated endoscopicallyJPRN-UMIN000010136ational cancer center hospital1,400
招募中
不适用
The observational study for the long-term follow-up of the participants of the preceding study "Prevention of Type II Endoleak with Embolization of IMA Before Endovascular Aneurysm Repair"Abdominal aortic aneurysmJPRN-UMIN000047713Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine86
尚未招募
4 期
A study of Denosumab in postmenopausal women and men with osteoporosis (weak and brittle bones) at high risk of fractureCTRI/2018/10/016049Intas Pharmaceuticals Ltd Biopharma Division
进行中（未招募）
1 期
ong term follow-up study of gene therapy trial for X-linked Retinitis PigmentosaEUCTR2018-000425-31-Outside-EU/EEAJanssen-Cilag International NV